Your browser doesn't support javascript.
loading
EZH2, an epigenetic driver of prostate cancer
Protein & Cell ; (12): 331-341, 2013.
Article in English | WPRIM | ID: wpr-757802
ABSTRACT
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Prostatic Neoplasms / Gene Expression Regulation, Neoplastic / DNA Methylation / Epigenesis, Genetic / Drug Therapy / Molecular Targeted Therapy / Polycomb Repressive Complex 2 / Enhancer of Zeste Homolog 2 Protein / Genetics Limits: Humans / Male Language: English Journal: Protein & Cell Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Prostatic Neoplasms / Gene Expression Regulation, Neoplastic / DNA Methylation / Epigenesis, Genetic / Drug Therapy / Molecular Targeted Therapy / Polycomb Repressive Complex 2 / Enhancer of Zeste Homolog 2 Protein / Genetics Limits: Humans / Male Language: English Journal: Protein & Cell Year: 2013 Type: Article